Management Discussion and Analysis 2017 P a g e | 2 Business Segment Performance In 2017, total revenue was THB 5,570 million, decreasing by 2.7 % from last year. Total revenue and EBITDA breakdown is as
Manufacture and sale of medicines, medical supplies and cosmetics segment 82,624 5.1 - - 82,624 100.0 รวม 1,614,607 100 1,637,162 100 (22,555) (1.4) In 2018, Sales and service revenue from the Company and its
5,346 0.8 Manufacture and sale of medicines, medical supplies and cosmetics segment 82,624 5.1 - - 82,624 100.0 รวม 1,614,607 100 1,637,162 100 (22,555) (1.4) In 2018, Sales and service revenue from the
that YCI shares were traded in big volumes. Such manipulation caused the price and the trading volume of YCI shares to be inconsistent with the normal market condition. In so doing, Siwasit was assisted
maximize market opportunities in 2018.” 2. Outlook General economic conditions are favorable: there is growing expectation that Q4 2017 GDP growth in Thailand will have accelerated to 4.5% y/y (versus 4.3
consolidated Saraburi Quicklime subsidiary (total 9 kilns) the core business is expected to operate on a capacity and market base 50% above Q2 2017. The increased capacity and market base in the core business
Search The Securities and Exchange Commission, Thailand About Us Our Roles Our Structure SEC Board Capital Market Supervisory Board SEC Executives Organization Chart
market pr etter value for m 2 Advanc paid segment focused on pro otential ARPU g ubscribers. 1H1 network qualit p in mobile ns and comp in mid to hig prepaid to po le revenue inc nt, which